Letters and Statements

ACCC joins a broad coalition of patients, advocacy organizations, cancer centers, and healthcare professionals to express support for the Reducing Hereditary Cancer Act. This crucial piece of legislation would address unacceptable care gaps in Medicare beneficiary access to genetic testing for hereditary cancer risk, evidence-based screening, and risk-reducing interventions, when medically necessary and appropriate.
Read the Letter

ACCC joined more than 250 organizations in asking congressional leadership to include the Access to Genetic Counselor Services Act (S. 1450/H.R. 2144) in an end-of-year legislative package. This piece of legislation would allow the Medicare program to directly reimburse genetic counselors, improving Medicare beneficiary access to comprehensive genetic counseling services.
Read the Letter

In a letter to congressional leadership, ACCC joined the American Society for Radiation Oncology (ASTRO) and more than 20 other organizations asking Congress to pass legislation before the end of the year to prevent significant Medicare payment cuts to radiation therapy services. These cuts largely stem from the 2023 Medicare Physician Fee Schedule, PAYGO sequester, and clinical labor price updates.
Read the Letter

ACCC sent a letter to House and Senate leaders this week, encouraging Congress to take action before the end of this year to mitigate significant Medicare payment cuts and improve patient access to high quality, efficient, and equitable cancer care. Without congressional intervention, significant reductions to Medicare payment will take effect in January 2023, including the proposed 4.42% reduction to the Medicare Physician Fee Schedule conversion factor and 4% Statutory Pay-As-You-Go sequester. Additional priorities include supporting the transition to value-based care, extending telehealth flexibilities beyond the COVID-19 public health emergency, and improving prior authorization processes in the Medicare Advantage program.
Read the Letter

In a letter to U.S. Food and Drug Administration (FDA) Commissioner Robert Califf, M.D., ACCC raises concern about recent delays in inspections of manufacturing facility that have led to interruptions in the approval of breakthrough therapies. We are particularly concerned when these delays impact novel treatments for diseases without FDA-approved therapies available and those that disproportionately impact minority communities.
Read the Letter